AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca PLC (LSE:AZN) boss Pascal Soriot has told Bloomberg that reports of his imminent departure from the drugmaker are “fake news.” Soriot, speaking at the European Society for Medical Oncology in Madrid, said: "I read these rumors and I can tell you - there's nothing further from the truth.

AstraZeneca boss Pascal Soriot dismisses exit talk

AstraZeneca PLC (LSE:AZN) has announced that its jointly developed lung cancer drug has been approved for use in the European Union. Enhertu, which has been co-developed with Daiichi Sankyo, received the green light for use in patients with advanced non-small cell lung cancer, whose tumours have an activating HER2 mutation.

AstraZeneca gains European approval for lung cancer drug

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term

The latest trading day saw Astrazeneca (AZN) settling at $64.42, representing a -1.26% change from its previous close.

Astrazeneca (AZN) Falls More Steeply Than Broader Market: What Investors Need to Know

AstraZeneca: Buy This Blue-Chip Bargain For A Richer Retirement

Gilead Sciences

AstraZeneca stock tumbled Wednesday after its experimental drug led to only a month's benefit over chemotherapy in lung cancer patients.

Why AstraZeneca's Disappointing Lung Cancer Update Also Tripped Gilead Stock

Novo Nordisk

Regeneron Pharmaceuticals

Roche Holding AG

NASHVILLE, Tenn. & TARRYTOWN, N.Y. & WILMINGTON, Del. & BAGSVAERD, Denmark & BASEL, Switzerland--(BUSINESS WIRE)--Meharry Medical College, along with partners Regeneron Genetics Center® (RGC™), AstraZeneca, Novo Nordisk, and Roche, today announced the launch of the Together for CHANGE™ (“Changing Healthcare for People of African Ancestry through an InterNational Genomics & Equity”) initiative to create better health care and outcomes for all. The Together for CHANGE initiative seeks to addr.

Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry

Shares in AstraZeneca fell more than 4% on Wednesday after the publication of an abstract on its experimental precision drug's use in lung cancer in a late-stage trial disappointed some analysts.

AstraZeneca shares fall as abstract for lung cancer trial data disappoints

Sophia Genetics SA

The three companies will collaborate to improve global access to advanced cancer testing and data, broadening access to cutting-edge science BOSTON and ROLLE, Switzerland , Oct. 18, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a category-defining software company and a global leader in data-driven medicine today announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK), a top cancer treatment and research institution, and AstraZeneca (LSE/STO/Nasdaq: AZN) to bring high quality, comprehensive cancer testing to a global scale. With this collaboration, the three leading organizations will further their shared goal to advance health equity on a global scale by providing inclusive access to comprehensive cancer testing worldwide.

SOPHiA GENETICS Enters New Collaboration with Memorial Sloan Kettering Cancer Center and AstraZeneca to Address Global Inequalities in Comprehensive Cancer Care

AstraZeneca PLC (LSE:AZN) shares were the biggest faller on the FTSE 100 on Wednesday, down 3.6%, with no obvious reason for the sell-off.  News and broker comments on the Anglo-Swedish drug giant seemed positive, following the release of late-stage clinical trials data from the company the day before.

AstraZeneca leads FTSE fallers with no obvious reason

The FDA accepts and grants priority review to AstraZeneca's (AZN) sNDA, seeking approval of Tagrisso combined with chemotherapy as a first-line treatment for EGFR-mutated advanced NSCLC. A decision is due in first-quarter 2024.

AstraZeneca's (AZN) Tagrisso Combo Gets FDA's Priority Review

The combination of AstraZeneca's cancer drug, Tagrisso, with chemotherapy has been been accepted and granted priority review by the U.S. Food and Drug Administration (FDA), the British drugmaker said on Monday.

AstraZeneca's Tagrisso-chemo combo given priority review in US

SUZHOU, China, and ROCKVILLE, Md. , Oct. 15, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has entered into a clinical collaboration with AstraZeneca Investment (China) Co., Ltd.

Ascentage Pharma and AstraZeneca Enter into Clinical Collaboration on the Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Combination with BTK Inhibitor Acalabrutinib in Treatment-Naïve Patients with First-Line CLL/SLL

Compass Therapeutics

Intuitive Surgical

During the pandemic era, several healthcare stocks skyrocketed. The focus was, however, on biopharma companies with an early-mover advantage related to the vaccine against Covid-19.

3 Healthcare Stocks To Make You The Millionaire Next Door: October Edition

Astrazeneca (AZN) concluded the recent trading session at $68.11, signifying a +0.15% move from its prior day's close.

Why the Market Dipped But (AZN) Gained Today

Adobe

Chevron

Pfizer

UnitedHealth Group

UnitedHealth, Chevron, AstraZeneca, Adobe and Pfizer are part of the Zacks Analyst Blog.

The Zacks Analyst Blog UnitedHealth, Chevron, AstraZeneca, Adobe and Pfizer

Fusion Pharmaceuticals

Data presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics FPI-2068 demonstrates anti-tumor activity in colorectal and lung tumor xenograft mouse models FPI-2068, developed as part of collaboration agreement with AstraZeneca, received IND clearance in 2Q 2023 HAMILTON, ON and BOSTON , Oct. 12, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of preclinical data for FPI-2068, a clinical stage bispecific IgG-based targeted alpha therapy (TAT) designed to deliver actinium-225 to various solid tumors that co-express EGFR-cMET. Fusion is jointly developing FPI-2068 with AstraZeneca (LSE/STO/Nasdaq: AZN) under the companies' multi-asset collaboration agreement.

Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting FPI-2068, a Novel Targeted Alpha Therapy for EGFR-cMET Expressing Cancers

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca announced today eight winners of the 2023 R&D Postdoctoral Challenge and agreed to fund their postdoctoral positions at one of the Company's strategic R&D centres in either Cambridge, UK, Gaithersburg or Boston, US or Gothenburg, Sweden. The R&D Postdoctoral Challenge stands out among traditional industry postdoctoral initiatives which usually offer pre-defined projects. The unique programme from AstraZeneca, now running for a second ye.

AstraZeneca Awards Funding to Eight Innovative Research Projects From Early-Career Scientists Around the World in Second R&D Postdoctoral Challenge

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to eliminate cancer as a cause of death with new data across its robust portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress, October 20-24, 2023. Nearly 100 abstracts will feature 19 approved and potential new medicines from AstraZeneca including two late-breaking Presidential Symposia and 26 oral presentations. Highlights include: TROPION-Lung01 Phase III trial of AstraZeneca and Daiichi Sankyo.

AstraZeneca advances scientific leadership across multiple cancers with first data from four pivotal Phase III trials at ESMO

WILMINGTON, Del.--(BUSINESS WIRE)--As the AstraZeneca Foundation celebrates its 30th anniversary, the organization has awarded 12 nonprofit organizations $2,170,318 in grants across eight US states and Washington, D.C., for innovative approaches to address healthcare disparities at the community level, a reflection of AstraZeneca's broader commitment to advance health equity efforts. Six grants were awarded through Creating Health Access for Next Generation Equity (CHANGE), its new signature pr.

Astrazeneca Foundation Awards 12 Nonprofit Organizations More Than $2M to Advance Health Equity

AstraZeneca is the best performing pharma in terms of five-year share price growth after Eli Lilly and Novo Nordisk. The latter two companies' valuation growth has been underpinned by a single weight loss / diabetes drug class. AZN is more diversified with a powerhouse oncology division. The oncology division revenues were 17% higher year-on-year in 1H23, while the CVRM division was 14% and rare disease 9%.

AstraZeneca: Hidden Gem Of The Pharma Sector Is A Great Buy Opportunity

Merck

Moderna

CRISPR Therapeutics

GlaxoSmithKline

Novartis

Sanofi

Scientists Katalin Karikó and Drew Weissman were awarded the Nobel prize this week for a discovery that went under the radar for many years, until it was found to hold the key to stabilising mRNA vaccines used in the fight against the Covid-19 pandemic.   The researchers own the patents to the nucleoside modification technology licensed out to drug companies such as BioNTech SE, where Karikó once worked, which developed an mRNA vaccine against Covid-19 with Pfizer Inc (NYSE:PFE), and Moderna Therapeutics Inc (NASDAQ:MRNA).

Nobel for mRNA: Which other biotech stocks might be overlooked?

NVIDIA

Starbucks

The Nasdaq 100 has been absolutely whipsawed in recent years. Two Nasdaq 100 stocks possess the necessary catalysts to fuel double-digit earnings growth.

2 Nasdaq 100 Stocks That Are Surefire Buys in October, and 1 to Avoid Like the Plague

AstraZeneca (AZN) agrees to pay $425 million to settle lawsuits related to heartburn drugs, Nexium and Prilosec.

AstraZeneca (AZN) Settles Heartburn Drugs Lawsuits for $425M

The payout will settle the claims of 11,000 people who said they weren't property warned Nexium and Prilosec could cause chronic kidney disease.

AstraZeneca Settles Lawsuits Alleging Heartburn Drugs Caused Kidney Disease For $425 Million

News for AstraZeneca Stock (AZN)